このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

再発/転移性HNSCCにおけるデュベリシブ + ドセタキセル

2026年9月4日 更新者:Kartik Sehgal, MD

PD-1阻害剤経験のある不治の頭頸部扁平上皮癌患者におけるデュベリシブとドセタキセルの第II相試験

This trial that is investigating a medication called duvelisib in combination with docetaxel for the treatment of squamous cell carcinoma of the head and neck (SCCHN) that has returned or spread outside the head and neck area.

The names of the study drugs involved in this study are:

  • Duvelisib (PI3K inhibitor)
  • Docetaxel chemotherapy

調査の概要

状態

完了

条件

介入・治療

詳細な説明

This multicenter, phase II open-label, single-arm trial will enroll participants with recurrent or metastatic (R/M), incurable squamous cell carcinoma of the head and neck (SCCHN) who have failed or discontinued PD-1 blockade in the first-line (1L) advanced disease setting, regardless of human papillomavirus (HPV) and smoking status, or PI3K pathway alteration status.

This research study involves the oral (taken by mouth) agent duvelisib with the intravenous (IV) chemotherapy agent docetaxel.

The names of the study drugs involved in this study are:

  • Duvelisib (PI3K inhibitor)
  • Docetaxel chemotherapy

The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits.

Participants will receive study treatment for up to 2 years and will be followed for 3 years.

It is expected that about 30 people will take part in this research.

This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational drug (duvelisib) to learn whether it works in treating a specific disease. "Investigational" means that the drug is being studied.

The U.S. Food and Drug Administration (FDA) has not approved duvelisib for this specific disease but has approved it for other uses (such as certain types of blood cancers). The FDA has approved docetaxel as a treatment option for head and neck cancer, as well as other cancer types.

研究の種類

介入

入学 (実際)

26

段階

  • フェーズ2

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • Massachusetts
      • Boston、Massachusetts、アメリカ、02115
        • Dana Farber Cancer Institute

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Participants must meet the following criteria on screening examination to be eligible to participate in the study:

  • Participants must have histologically confirmed squamous cell carcinoma of the head and neck (SCCHN) with evidence of recurrent, metastatic (R/M) or advanced, incurable disease from any mucosal subsite including oral cavity, oropharynx, larynx, hypopharynx, nasal cavity, and the paranasal sinuses.

  • Participants must have at least one RECIST v1.1 measurable lesion, as defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) ≥1 cm with CT scans or MR imaging.

  • Must have had at least 1, but no more than 2, prior lines of prior systemic therapy for R/M SCCHN; one of these lines should have included PD-1/L1 blockade

    • Platinum-based therapy as part of definitive/adjuvant or curative-intent treatment can count as 1 prior line of therapy if the subject progressed within 6 months of receiving therapy.
    • At least 2 weeks must have elapsed since the end of prior chemotherapy, biological agents (3 weeks for anti-cancer monoclonal antibody containing regimens) or any investigational drug product, with adequate recovery of treatment-related toxicity to NCI CTCAE Version 5.0 grade ≤1 (or tolerable grade 2) or back to baseline (except for alopecia or peripheral neuropathy).
  • Be ≥18 years of age on the day of signing informed consent.

  • Must provide prior data on tumor PD-L1 expression status and HPV status, if available

  • Have a performance status of 0 or 1 on the ECOG Performance Scale

  • Participants must have adequate organ and marrow function as defined below (within 14 days prior to study registration):

    • absolute neutrophil count ≥ 1,000/mcL
    • hemoglobin ≥ 9 g/dL
    • platelets ≥ 100,000/mcL
    • total bilirubin ≤ upper limit of normal (ULN)
    • AST(SGOT)/ALT(SGPT) ≤ 2.5x institutional ULN (or ≤ 1.5x institutional ULN if concomitant with alkaline phosphatase >2.5x institutional ULN) or ≤ 5x ULN for those with liver metastases
    • serum creatinine ≤ 1.5x ULN OR creatinine clearance ≥ 60 mL/min/1.73 m2 for participants with creatinine levels above 1.5x ULN
    • coagulation profile INR ≤ 1.5x ULN unless the participant is receiving an anticoagulant
  • Baseline tumor measurements must be documented from imaging within 28 days prior to study registration.

  • Female subjects of childbearing potential should have a negative urine or serum pregnancy test within 7 days of study registration. Female subjects of childbearing potential should have a negative urine or serum pregnancy test repeated within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.

  • Female and male subjects of childbearing potential must agree to use an adequate method of contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and 4 months after completion of stud drug administration. Contraception is required before starting the first dose of study medication through 120 days after the last dose of study medication. Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject.

  • Be willing and able to provide written informed consent for the trial.

Exclusion Criteria:

  • Participants who exhibit any of the following conditions at screening will not be eligible for admission into the study.

  • Have been previously treated with 3 or more lines of systemic therapy for R/M SCCHN.

    -- Have received treatment with a prior PI3K pathway inhibitor

  • Have received radiation therapy (RT) within 14 days of the first dose of duvelisib on study.

  • Participant has known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Subjects with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging and off systemic steroids for at least 4 weeks prior to the first dose of study treatment), and have no evidence of new or enlarging brain metastases. This exception does not include carcinomatous meningitis which is excluded regardless of clinical stability, because of the poor prognosis and progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events.

  • Concurrent administration of other cancer specific therapy or investigational agents during the course of this study.

  • Uncontrolled intercurrent illness including but not limited to ongoing or active infection; evidence of symptomatic congestive heart failure, unstable angina pectoris, stroke, or ventricular arrhythmia within 6 months of enrollment.

  • Have received a live or live attenuated vaccine within 4 weeks of the first dose of duvelisib.

  • Have received medications or consumed foods that are strong inhibitors or inducers of cytochrome P450 (CYP3A) within 2 weeks of, or while on, duvelisib.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:なし
  • 介入モデル:単一グループの割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Duvelisib plus Docetaxel chemotherapy

Participants will receive duvelisib by mouth twice daily,dosage per protocol continuously (days 1-21 of a 21-day cycle) with a 7-day lead-in planned prior to the start of taxane therapy.

Docetaxel at via IV will be delivered on day 1 of each 21-day cycle.

Treatment will continue for 24-months or until unacceptable toxicity, progression, or death.

Duvelisib capsules should be swallowed whole with a glass of water (approximately 8 ounces).

Advise patients not to open, break, or chew the capsules. Duvelisib may be administered without regard to meals; however, subjects should avoid grapefruit and grapefruit juice while on duvelisib.

continue for up to 24 months.

他の名前:
  • VS-0145

Docetaxel chemotherapy once every 21 days (by intravenous infusion) over about 30- 60 minutes at each visit. This will continue for up to 24 months

他の名前:
  • タキソテール

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Best Overall Response (BOR) Rate
時間枠:Median time on treatment was 2.3 months (range 0.7-21.9 months)

BOR rate was defined as the proportion of participants that experienced complete response (CR) or partial response (PR) on treatment based on RECIST 1.1 criteria. Per RECIST 1.1 for target lesions: CR is complete disappearance of all target lesions and PR is at least a 30% decrease in the sum of longest diameter (LD) of target lesions, taking as reference baseline sum LD. PR or better overall response assumes at a minimum incomplete response/stable disease (SD) for the evaluation of non-target lesions and absence of new lesions.

Median time on treatment was 2.3 months (range 0.7-21.9 months)

二次結果の測定

結果測定
メジャーの説明
時間枠
Median Overall Survival (OS)
時間枠:The median follow-up time was 6.5 months (range 0.7 - 26 months).

OS based on the Kaplan-Meier method was defined as the time from registration to death due to any cause, or censored at date last known alive.

The median follow-up time was 6.5 months (range 0.7 - 26 months).
Median Progression Free Survival (PFS)
時間枠:Median follow-up time was 2.3 months (range 0.7-21.9 months)

PFS based on the Kaplan-Meier method was defined as the time from registration to the earlier of progression or death due to any cause. Participants alive without disease progression are censored at date of last disease evaluation. Per RECIST 1.1 for target lesions: PD is at least a 20% increase in sum LD, taking as reference the smallest sum on study with at least 5 mm absolute increase. For non-target lesions, progression-free means no new lesions or unequivocal progression on existing non-target lesions or not evaluated.

Median follow-up time was 2.3 months (range 0.7-21.9 months)
Duration of Response (DOR)
時間枠:Median follow-up time was 2.3 months (range 0.7-21.9 months)

DOR was measured from the time measurement criteria are met for CR or PR (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented (taking as reference for progressive disease the smallest measurements recorded since the treatment started. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.

Median follow-up time was 2.3 months (range 0.7-21.9 months)
Number of Participants With Treatment Related Adverse Events Per CTCAE 5.0
時間枠:Median follow-up time was 2.3 months (range 0.7-21.9 months)

The number of participants who experienced the treatment-related adverse events per CTCAE 5.0 during the time of treatment.

Median follow-up time was 2.3 months (range 0.7-21.9 months)
Change of QLQ H&N 35 From Cycle 1 to Cycle 4
時間枠:Up to 3 months

The QLQ H&N35 incorporates seven multi-item scales that assess pain, swallowing, senses (taste and smell), speech, social eating, social contact and sexuality. There are also eleven single items. The score range from 0 to 100.

For all items and scales, high scores indicate more problems, so negative difference indicates better QoL (less problems) at C4D1 compared to C1D1.

Up to 3 months

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

協力者

捜査官

  • 主任研究者:Kartik Sehgal, MD、Dana-Farber Cancer Institute

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2021年10月14日

一次修了 (実際)

2023年10月1日

研究の完了 (実際)

2024年6月13日

試験登録日

最初に提出

2021年9月8日

QC基準を満たした最初の提出物

2021年9月15日

最初の投稿 (実際)

2021年9月27日

学習記録の更新

投稿された最後の更新 (実際)

2026年9月29日

QC基準を満たした最後の更新が送信されました

2026年9月4日

最終確認日

2026年9月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • 21-393

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to Sponsor Investigator or designee. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.

IPD 共有時間枠

Data can be shared no earlier than 1 year following the date of publication

IPD 共有アクセス基準

Contact the Belfer Office for Dana-Farber Innovations (BODFI) at innovation@dfci.harvard.edu

IPD 共有サポート情報タイプ

  • STUDY_PROTOCOL
  • SAP

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。